Day One

A cross-disciplinary panel bringing together leaders working across the most advanced and emerging applications of LNP delivery, including srRNA, gene editing, in vivo cell therapy, oncology, autoimmune disease and protein replacement.

• Compare delivery requirements across different therapeutic modalities
• Identify where LNPs are already working vs where they are still failing
• Understand how application choice impacts design, toxicity and manufacturability
• Evaluate which areas are overhyped vs commercially viable
• Explore how hybrid systems (lipids, polymers, peptides) are expanding capability

• Evaluate the role of polymers in LNP systems, identify sources of added complexity and toxicity and redesign formulations to maintain performance while simplifying composition
• Optimise lipid-only formulations, improve encapsulation efficiency and delivery performance, reduce variability and enhance manufacturability
• Assess the impact of polymer-free systems on safety, immunogenicity and scalability, enable more robust and clinically viable mRNA delivery platforms

As this community unites, this session will provide valuable networking time with your peers, enabling you to forge new and lasting connections.

• Map intracellular LNP structure and integrity using advanced cryo-EM imaging
• Investigate endosomal escape mechanisms under physiologically relevant conditions
• Link nanoparticle morphology and phase behavior to cell-specific targeting outcomes
• Generate early in vitro and in vivo insights to inform rational LNP design beyond trial-and-error

• Rational design approaches are applied for tailoring lipid and LNP architecture
• Tailored formulations with tunable immunogenicity and precise targeting specificity are provided
• Formulations allow for repeat dosing in therapeutic settings
• Improved safety and reduced reactogenicity were demonstrated in a clinical study

• Apply single particle methods, reveal hidden variability and improve formulation understanding
• Compare analytical platforms, select appropriate tools and increase data reliability
• Link particle heterogeneity, predict performance and reduce development risk

• Analyse patent trends, identify freedom to operate and reduce legal risk
• Evaluate academic outputs, identify commercial potential and guide investment decisions
• Structure IP strategy, protect innovation and enhance company value

A practical, discussion-led session where participants work through real regulatory scenarios, aligning analytical, CMC and development strategies with phase-appropriate expectations to accelerate clinical progression.

• Clarify what “phase-appropriate” development really means in practice
• Identify where teams over-engineer and over-characterise LNP systems
• Understand how to prioritise critical data vs nice-to-have data
• Align analytical, CMC and clinical strategies with regulatory expectations
• Reduce delays caused by misaligned development strategies

This is your opportunity to contribute to the conversation and share your cutting-edge research with this community while discovering exciting work carried out by your peers. To submit a poster, please contact info@hansonwade.com.

A practical, end-to-end simulation where participants work through the full lifecycle of an LNP therapy, integrating innovation, CMC and regulatory decision-making to successfully move a candidate toward clinical readiness.

• A practical framework for evaluating LNP designs beyond scientific performance
• Clear understanding of how CMC and regulatory constraints reshape innovation
• Improved ability to make phase-appropriate decisions that accelerate timelines
• Real insight into where most LNP programs fail or stall before clinic